Aerosmith Postpones Tour Dates After Steven Tyler Suffers ‘Bleeding’ Vocal Cords

Several dates for Aerosmith’s farewell tour — billed as the rock band’s final run after more than 50 years together — have been postponed after frontman Steven Tyler sustained an injury that left him with “bleeding” vocal cords during their stop at the UBS Arena on Sept. 9.

“I’m heartbroken to say I have received strict doctor’s orders not to sing for the next thirty days,” Tyler shared in a statement on Aerosmith’s social media. “I sustained vocal cord damage during Saturday’s show that led to subsequent bleeding. We’ll need to postpone a few dates so that we can come back and give you the performance you deserve.”

More from Variety

Six dates have been rescheduled to 2024, starting in January and running through the end of February, with stops in Detroit, Chicago, Washington, D.C., Toronto, Raleigh and Cleveland. The band has also announced that all previously purchased tickets will be honored on the new dates and that refunds are available at the point of purchase for those no longer able to attend. See the full list of rescheduled dates below.

Aerosmith has completed three out of 40 dates since the tour’s launch on Sept. 2 in Philadelphia. Last December, Aerosmith canceled the final two dates of their Las Vegas residency due to an undisclosed illness of Tyler’s. Before that, they had pushed back a slate of dates to allow Tyler to voluntarily enter a treatment program so the singer could address his addiction issues — a result of a relapse after he used pain medication following foot surgery.


Monday Jan 29 2024 – Detroit, MI – Little Caesars Arena
Wednesday Feb 14 2024 – Chicago, IL – United Center
Saturday Feb 17 2024 – Washington, DC – Capital One Arena
Wednesday Feb 21 2024 – Toronto, ON – Scotiabank Arena
Monday Feb 26 2024 – Raleigh. NC – PNC Arena
Thursday Feb 29 2024 – Cleveland, OH – Rocket Mortgage FieldHouse

Best of Variety

Sign up for Variety’s Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.

Click here to read the full article.